Destelbergen, Belgium

Frans Van Roy



Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2004-2009

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Frans Van Roy

Introduction

Frans Van Roy is a notable inventor based in Destelbergen, Belgium, recognized for his significant contributions to the field of biotechnology. With a total of three patents to his name, he has made strides in understanding and addressing critical health issues.

Latest Patents

One of his latest patents is a method to control tumor progression and invasiveness. This invention describes a method of modulating E-cadherin mediated cell adhesion, specifically utilizing hECRep1a and its homologues to influence tumor cell invasiveness. Another important patent relates to a novel α-catenin, which exhibits a specific expression pattern primarily in the heart and testis. This invention is significant for its potential applications in predicting, diagnosing, and treating cadherin-catenin related diseases, particularly cardiomyopathies and male infertility.

Career Highlights

Frans Van Roy has worked with esteemed organizations such as the Flemish Interuniversity Institute for Biotechnology and Ghent University. His work in these institutions has allowed him to further his research and contribute to advancements in biotechnology.

Collaborations

Throughout his career, he has collaborated with notable colleagues, including Barbara Janssens and Ann Van Landschoot. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

Frans Van Roy's innovative work in biotechnology, particularly in cancer research and reproductive health, showcases his commitment to advancing medical science. His patents reflect a deep understanding of complex biological processes and hold promise for future medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…